All In Biotech

Drug Trial Radar · NCT06732323

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

A Randomized, Open-label, Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy as First-line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 504 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

504

Planned (sponsor's estimate)

Start

Sep 4, 2025

Primary completion

Jun 2027

Study completion Jul 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.

Conditions

  • Triple-Negative Breast Cancer (TNBC)

Interventions

  • ESG401Drug

    IV infusion on day 1,8, and 15 of each 28 day cycle

  • Investigator's Choice ChemotherapyDrug

    Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)Time frame: Randomization up to approximately 28 months
  2. Overall Survival (OS)Time frame: Randomization up to approximately 41 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.